Dehydroepiandrosterone induces a neuroendocrine phenotype in nerve growth factor-stimulated chromaffin pheochromocytoma PC12 cells.
The adrenal androgen dehydroepiandrosterone (DHEA) is produced in the inner zone of the adrenal cortex, which is in direct contact to adrenal medullary cells. Due to their close anatomical proximity and tightly intermingled cell borders, a direct interaction of adrenal cortex and medulla has been postulated. In humans congenital adrenal hyperplasia due to 21-hydroxylase deficiency results in androgen excess accompanied by severe adrenomedullary dysplasia and chromaffin cell dysfunction. Therefore, to define the mechanisms of DHEA action on chromaffin cell function, we investigated its effect on cell survival and differentiation processes on a molecular level in the chromaffin cell line PC12. DHEA lessened the positive effect of NGF on cell survival and neuronal differentiation. Nerve growth factor (NGF)-mediated induction of a neuronal phenotype was inhibited by DHEA as indicated by reduced neurite outgrowth and decreased expression of neuronal marker proteins such as synaptosome-associated protein of 25 kDa and vesicle-associated membrane protein-2. We examined whether DHEA may stimulate the cells toward a neuroendocrine phenotype. DHEA significantly elevated catecholamine release from unstimulated PC12 cells in the presence but not absence of NGF. Accordingly, DHEA enhanced the expression of the neuroendocrine marker protein chromogranin A. Next, we explored the possible molecular mechanisms of DHEA and NGF interaction. We demonstrate that NGF-induced ERK1/2 phosphorylation was reduced by DHEA. In summary, our data show that DHEA influences cell survival and differentiation processes in PC12 cells, possibly by interacting with the ERK1/2 MAPK pathway. DHEA drives NGF-stimulated cells toward a neuroendocrine phenotype, suggesting that the interaction of intraadrenal steroids and growth factors is required for the maintenance of an intact adrenal medulla.
Ziegler
Christian G
CG
University Hospital Carl Gustav Carus, Medical Clinic III, University of Dresden, 01307 Dresden, Germany.
Sicard
Flavie
F
Lattke
Peter
P
Bornstein
Stefan R
SR
Ehrhart-Bornstein
Monika
M
Krug
Alexander W
AW
D000310:Adrenal Gland Neoplasms / Q000378:metabolism / Q000473:pathology*; D000818:Animals; D015415:Biomarkers / Q000378:metabolism; D002454:Cell Differentiation / Q000187:drug effects*; D002470:Cell Survival / Q000187:drug effects; D019439:Chromaffin Cells / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D003687:Dehydroepiandrosterone / Q000494:pharmacology*; D004298:Dopamine / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D048052:Mitogen-Activated Protein Kinase 3 / Q000378:metabolism; D020932:Nerve Growth Factor / Q000494:pharmacology*; D016501:Neurites / Q000187:drug effects; D018358:Neuroendocrine Tumors / Q000378:metabolism / Q000473:pathology*; D016716:PC12 Cells; D010641:Phenotype; D010673:Pheochromocytoma / Q000378:metabolism / Q000473:pathology*; D051381:Rats; D050825:Synaptosomal-Associated Protein 25 / Q000378:metabolism
D015415:Biomarkers; C494210:Snap25 protein, rat; D050825:Synaptosomal-Associated Protein 25; D003687:Dehydroepiandrosterone; D020932:Nerve Growth Factor; D048052:Mitogen-Activated Protein Kinase 3; D004298:Dopamine